Compare Abbott Laboratories (ABT) vs Phillips 66 (PSX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Phillips 66 — how do they compare? Abbott Laboratories trades at $95.25 (market cap $166.94B), while Phillips 66 trades at $186.5 (market cap $71.70B). The key difference: Abbott Laboratories is far larger — about 2.3× Phillips 66's market cap, and Phillips 66 pays the higher dividend (2.84%). Which is the better fit depends on your goals.
| ABT | PSX | |
|---|---|---|
Market Cap | $166.94B | $71.70B |
Sector | Health | Energy |
52-Week High | $136.62 | $188.28 |
52-Week Low | $82.57 | $118.37 |
Enterprise Value | $193.69B | $93.68B |
Dividend Yield | 2.63% | 2.84% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Phillips 66 (PSX) trades at $178.84, up 1.37% with a bullish technical signal and strong analyst consensus. The stock shows improving fundamentals with recent earnings beats, a 3.07% net margin, and attractive valuation at P/E 17.52 and P/S 0.54. Recent news highlights resilience amid softer oil prices, supported by diversified operations and a $1.27 dividend payment.
Outlook remains positive with a $190.38 price target, though risks include refining volatility from Hormuz disruptions and declining revenue trends. The stock offers value through stable cash flow and dividend income, but investors should monitor geopolitical impacts on earnings and energy market fluctuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Phillips 66
Phillips 66 is an independent refiner with 12 refineries that have a total crude throughput capacity of 2.0 million barrels per day, or mmb/d, after converting its 255 mb/d Alliance refinery to a terminal. The midstream segment comprises extensive transportation and NGL processing assets. It also includes its DCP Midstream joint venture, which holds 45 natural gas processing facilities, 11 NGL fractionation plants, and a natural gas pipeline system with 58,000 miles of pipeline. Its CPChem chemical joint venture operates facilities in the United States and the Middle East and primarily produces olefins and polyolefins.
Read more on PSX →
